Published in Br J Cancer on March 31, 2015
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov (2015) 1.30
Targeting metastasis. Nat Rev Cancer (2016) 1.26
The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients. Oncotarget (2015) 0.99
Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget (2016) 0.90
Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types. Int J Mol Sci (2016) 0.88
EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. Oncoimmunology (2015) 0.86
Role of the immune system in the peritoneal tumor spread of high grade serous ovarian cancer. Oncotarget (2016) 0.84
IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget (2015) 0.84
Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83
Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis. Breast Cancer Res (2016) 0.81
The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract (2016) 0.81
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells. Oncoimmunology (2016) 0.80
Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol (2017) 0.79
Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int J Clin Oncol (2016) 0.79
PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget (2016) 0.79
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognostic. Oncotarget (2017) 0.78
Exogenous IL-33 overcomes T cell tolerance in murine acute myeloid leukemia. Oncotarget (2016) 0.78
Co-inhibitory blockade while preserving tolerance: checkpoint inhibitors for glioblastoma. Immunol Rev (2017) 0.78
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade. Oncoimmunology (2016) 0.78
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat Commun (2017) 0.77
Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. Oncotarget (2016) 0.76
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. J Immunother Cancer (2016) 0.76
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide. J Immunother Cancer (2016) 0.75
High-dose irradiation in combination with toll-like receptor 9 agonist CpG oligodeoxynucleotide 7909 downregulates PD-L1 expression via the NF-κB signaling pathway in non-small cell lung cancer cells. Onco Targets Ther (2016) 0.75
Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control. Oncotarget (2017) 0.75
Chemoradiation Increases PD-L1 Expression in Certain Melanoma and Glioblastoma Cells. Front Immunol (2016) 0.75
A novel and effective method to generate human porcine-specific regulatory T cells with high expression of IL-10, TGF-β1 and IL-35. Sci Rep (2017) 0.75
Programmed death-ligand 1 is prognostic factor in esophageal squamous cell carcinoma and is associated with epidermal growth factor receptor. Cancer Sci (2017) 0.75
Induction of PD-L1 expression by epidermal growth factor receptor-mediated signaling in esophageal squamous cell carcinoma. Onco Targets Ther (2017) 0.75
JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology (2017) 0.75
CD8 T-cell regulation by T regulatory cells and the programmed cell death protein 1 pathway. Immunology (2017) 0.75
Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma. J Immunother Cancer (2017) 0.75
Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. Oncoimmunology (2017) 0.75
ROS mediates interferon gamma induced phosphorylation of Src, through the Raf/ERK pathway, in MCF-7 human breast cancer cell line. J Cell Commun Signal (2016) 0.75
Cytokines in immunogenic cell death: Applications for cancer immunotherapy. Cytokine (2017) 0.75
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget (2017) 0.75
IL-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Sci (2017) 0.75
Lack of IL-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Cancer Sci (2017) 0.75
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest (2017) 0.75
Kaposi's Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes. MBio (2017) 0.75
Monocyte programmed death ligand-1 expression is an early marker for predicting infectious complications in acute pancreatitis. Crit Care (2017) 0.75
PD-L1/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma. Oncotarget (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med (2000) 19.81
Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53
Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol (2002) 14.75
Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med (2012) 13.12
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A (2002) 12.39
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A (2007) 7.49
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med (2013) 5.82
PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res (2004) 5.59
CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 4.97
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res (2005) 4.94
Influence of tumour micro-environment heterogeneity on therapeutic response. Nature (2013) 4.78
PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol (2006) 3.50
Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun (2013) 2.94
Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol (2011) 2.67
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Prognostic significance of tumor-associated macrophages in solid tumor: a meta-analysis of the literature. PLoS One (2012) 2.14
Identification of genes selectively regulated by IFNs in endothelial cells. J Immunol (2007) 1.87
Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother (2008) 1.38
PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin Cancer Res (2013) 1.17
Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer (2000) 1.17
Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol (2009) 1.15
The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer (2011) 1.05
Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. Clin Cancer Res (2007) 1.02
The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol (2009) 0.99
Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells. Lymphokine Cytokine Res (1993) 0.98
Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res (2000) 0.93
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple immune factors. Clin Immunol (2011) 0.93
PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells. Nephrol Dial Transplant (2007) 0.90
Establishment of an immortalised human ovarian surface epithelial cell line without chromosomal instability. Br J Cancer (2005) 0.88
Immune therapy for ovarian cancer: promise and pitfalls. Int Rev Immunol (2011) 0.88
Myeloid-derived suppressor cells modulate immune responses independently of NADPH oxidase in the ovarian tumor microenvironment in mice. PLoS One (2013) 0.83
Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res (2006) 0.83
Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor prognostic ovarian cancers with high levels of COX expression. Mod Pathol (2008) 0.83
Flow cytometric quantification of intraperitoneal free tumor cells in patients with peritoneal metastasis. Cytometry B Clin Cytom (2013) 0.81
Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. Stem Cells (2010) 0.80
Reliable pre-eclampsia pathways based on multiple independent microarray data sets. Mol Hum Reprod (2014) 0.79